X
66.04
-2.22 (-3.25%)
| Penutupan Terdahulu | 68.26 |
| Buka | 68.16 |
| Jumlah Dagangan | 695,684 |
| Purata Dagangan (3B) | 1,446,813 |
| Modal Pasaran | 6,383,793,152 |
| Harga / Jualan (P/S) | 591.55 |
| Harga / Buku (P/B) | 4.93 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -969.84% |
| EPS Cair (TTM) | -3.22 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.23% |
| Nisbah Semasa (MRQ) | 17.66 |
| Aliran Tunai Operasi (OCF TTM) | -196.85 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -128.49 M |
| Pulangan Atas Aset (ROA TTM) | -22.03% |
| Pulangan Atas Ekuiti (ROE TTM) | -31.60% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Xenon Pharmaceuticals Inc. | Bercampur | Menaik |
AISkor Stockmoo
0.3
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.33 |
|
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.14% |
| % Dimiliki oleh Institusi | 103.51% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |